Superworth

Halozyme Therapeutics EV/EBIT HALO

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2018.

Today, Nov 2, 2026
17.8×
9-year median
20.5×
Against its 9-year history
33rd
percentile: 0 is its lowest day, 100 its highest
9-year range
11.0× to 105×
Peer median
23.8×

Halozyme Therapeutics' EV/EBIT is 17.8× as of Nov 2, 2026.

That is below its 9-year median of 20.5×, lower than on 67% of days in the last 9 years.

Over that time it ranged from 11.0× in Dec 2025 to 105× in Feb 2021.

The median for 10 biotech stocks of a similar size is 23.8×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far17.8×11.5×18.0×
202512.1×11.0×17.3×
202414.6×13.9×22.5×
202319.0×18.1×35.0×
202235.8×15.3×37.2×
202119.0×15.3×105×
202090.1×79.6×90.5×
201938.1×32.1×38.1×
201831.0×21.6×36.7×

Against its peers

Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.

CompanyEV/EBIT
HALOHalozyme Therapeutics17.8×
NBIXNeurocrine Biosciences18.6×
EXELExelixis16.8×
TECHBIO-TECHNE45.0×
ALNYAlnylam Pharmaceuticals19.2×
RGENRepligen156×
INCYIncyte28.3×
KRYSKrystal Biotech40.1×
UTHRUnited Therapeutics16.3×
ONCBeOne Medicines40.2×
ADMAAdma Biologics11.3×
Peer median23.8×

Where Halozyme Therapeutics ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Halozyme Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.